SCCA Breast Cancer Clinical Trials
The Seattle Cancer Care Alliance Breast Cancer Research Program has a multidisciplinary approach to cancer research focusing on the diagnosis and treatment of cancer with novel imaging and cancer treatment agents. We put particular emphasis on imaging trials that measure the ability of MRIs and PET imaging to predict response to treatment. We also explore targeted therapy including those treatments aimed at specific processes of cancer cell growth, division or life cycle or, in some cases, the blood vessels nourishing a tumor.
To find a clinical trial:
- View the Breast Cancer Trial Finder, where trials are organized by disease status (e.g., "Metastatic ER", "Metastatic HER2+").
- Click here to view a listing of all open breast cancer trials.
- To see a list of all of SCCA's most recently opened clinical trials, follow our Twitter feed @SCCA_Trials. Likewise, the SCCABlog also regularly lists recently opened trials as well.
Our current high priority trials include:
For patients with metastatic disease:
- Triple Negative Gen (6628)
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
For patients with HER2-positive breast cancer:
- Kadcyla + Pertuzumab vs. Herceptin + Pertuzumab + Taxane for HER2-positive Breast Cancer (UW13051-KAITLIN Trial)
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus A Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy In Patients With Operable Her2 Positive Primary Breast Cancer
- FDG PET (7159)
FDG PET (Reproducibility Across Centers)
For patients with newly diagnosed disease:
- Early Assessment Challenge Grant (7043)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy
Our faculty also participate in cooperative group trials through the Southwest Oncology Group (SWOG), the American College of Surgeons Oncology Group (ACOSOG) and the American College of Imaging Network (ACRIN).